Pulsenmore Ltd Dossier
Qualitative Analysis
Business overview
Pulsenmore Ltd. (NASDAQ: PLSM, TASE: PLSM) is an innovative digital health company specializing in the development, production, and marketing of self-scan home ultrasound devices designed for remote clinical diagnosis and prenatal monitoring. Founded in 2014 and headquartered in Omer, Israel, the company's flagship platform combines proprietary handheld ultrasound hardware, a patient-facing mobile application that guides self-scanning, and a secure cloud-based clinician dashboard for remote image review and consultation. Pulsenmore's technology is cleared for commercial distribution in several global markets, including the United States, the European Union, the United Kingdom, Switzerland, Australia, Brazil, Colombia, and Israel. Notably, its Pulsenmore ES system is the first and only FDA-authorized home-use prenatal ultrasound system, establishing a strong regulatory foundation for expanding remote maternal-fetal care.
Research as of 24 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Launching and scaling the FDA-authorized Pulsenmore ES home-use prenatal ultrasound platform in the United States through clinical partnerships and virtual care integrations.
Expected impact: Establishes a strong commercial footprint in the world's largest healthcare market, targeting underserved maternal care deserts.
Expanding the home ultrasound platform beyond individual measurements toward advanced prenatal assessments and software-based clinical applications (SaaS modules).
Expected impact: Aims to unlock high-margin recurring revenue streams and provide clinicians with more comprehensive remote monitoring tools.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Integrates Pulsenmore's FDA-authorized home ultrasound platform into Ouma Health's established virtual maternity care model across the United States, expanding access to remote prenatal care.
Terms: Not publicly disclosed, but expected to drive commercial adoption and expand U.S. market presence.
Marks Pulsenmore's first commercial agreement in the United States, enabling high-risk pregnancy patients to benefit from remote monitoring and reducing unnecessary clinic visits.
Terms: CFFM will purchase Pulsenmore ES home ultrasound services.
Enables the marketing and deployment of Pulsenmore's home ultrasound devices and at-home follicular monitoring services within Israel's largest health service organization.
Terms: Not publicly disclosed.